Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04167163 · ClinicalTrials.gov registry record · Phase 4
Abaloparatide Before Total Knee Arthroplasty
A Phase 4 study of Osteoporosis and Arthroplasties, Knee Replacement, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT04167163: Completed Phase 4 study of Osteoporosis and Arthroplasties, Knee Replacement, sponsored by University of Wisconsin, Madison.
NCT04167163 is a Phase 4 study of Osteoporosis and Arthroplasties, Knee Replacement that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 58 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04167163, a Phase 4 study of Osteoporosis and Arthroplasties, Knee Replacement, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss.
Primary Outcome
Bone mineral density change at the 25% ROI of the surgical leg. Dual-energy X-ray absorptiometry (DXA) measured BMD was obtained at a point (ROI) 25% the length of the total surgical femur. Percent change at 25% ROI was calculated from baseline to 18 months.
Conditions Studied
Interventions
- DRUG Abaloparatide
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2020-01-10 |
| Est. Completion | 2025-04-03 |
| Phase | Phase 4 |
What the finished NCT04167163 record still lists
NCT04167163 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which Abaloparatide is the first listed.
NCT04167163 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04167163 about?
NCT04167163 is a clinical study titled "Abaloparatide Before Total Knee Arthroplasty". The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss.
What is the current status of trial NCT04167163?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2020-01-10. Estimated completion is 2025-04-03.
What conditions does trial NCT04167163 study?
This clinical trial studies the following conditions: Osteoporosis, Arthroplasties, Knee Replacement.
What interventions are being tested in trial NCT04167163?
The interventions under investigation include: Abaloparatide (DRUG).
Who is sponsoring clinical trial NCT04167163?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04167163 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04167163's enrollment target sits among peer trials
58 51st of 84 higher than 34 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preserving Geriatric Muscle With an Osteoporosis Medication
RECRUITING · Phase 4
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI